Sponsored Links
MedicalResources
| ImmuneRegen BioSciences(R) Initiates Homspera(R) Studies Against Global Influenza Threat |
 |
 |
 |
| Medical News - Bird Flu | |||
|
ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Read more: Bird Flu / Avian Flu News From Medical News Today
|